Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABR + Axitinib + Toripalimab in Oligometastatic ccRCC
NCT07744932Phase 2Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Aug 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib, toripalimab in clear cell renal cell carcinoma (ccRCC), sponsored by The Fourth Hospital of Hebei Medical University. Started Aug 2026; status: recruiting.
02
Drugs
axitinibtoripalimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07744932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07744932.